CClinicalTrials.gg
CompletedNCT07071545PA-NormalWtDMUpdated Jul 17, 2025

Effect of Regular Physical Activity in Normal-Weight Individuals With Type 2 Diabetes and Abdominal Obesity

An observational study in Diabetes (DM) and Physical Activity, sponsored by Samsung Medical Center. Completed. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Samsung Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
249,247
Sex
All
01

Study summary

Individuals with T2DM accompanied by abdominal obesity tend to experience worse clinical outcomes. To identify modifiable factors that may improve these outcomes, the investigators conducted a retrospective cohort study using data from the Korean National Health Insurance Service (K-NHIS) database to evaluate the impact of regular physical activity.

Read the detailed description

It is well established that patients with T2DM and abdominal obesity have worse clinical outcomes. This holds true even among individuals with a normal body weight but central (abdominal) obesity. In this study, the investigators aimed to determine whether engaging in regular physical activity (defined as vigorous exercise at least three times per week) is associated with improved clinical outcomes in normal-weight individuals with abdominal obesity. Specifically, we compared the incidence of MACCE between normal-weight patients with type 2 diabetes who had abdominal obesity and those who did not.

02

Conditions studied

  • Diabetes (DM)
  • Physical Activity

Keywords

  • abdominal obesity
  • physical activity
  • Diabetes mellitus
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 249,247 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who were newly diagnosed with T2DM and had a normal body weight at the time of diagnosis.

Inclusion criteria

- Patients who were newly diagnosed with T2DM and had a normal body weight at the time of diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Patients with any pre-existing diabetes-related complications
  • Patients who were overweight or obese based on BMI criteria
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
249,247 participants (actual)
Patient registry
No

Groups and cohorts

  • Abdominal obesity

    Individuals were classified as having abdominal obesity.

    Behavioral: Regular physical activity · Behavioral: No regular physical activity

  • Without abdominal obesity

    Individuals were classified as not having abdominal obesity.

Interventions

  • BehavioralRegular physical activity

    Moderate-to-vigorous physical activity at least three times per week.

  • BehavioralNo regular physical activity

    The group that did not engage in physical activity according to the guidelines

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac and cerevrovascular events (MACCE)

    Composite of all-cause death, myocardial infarction, ischemic stroke, heart failure

    Time frame: 10 years after diagnosed T2DM

Secondary outcomes

  1. All cause death

    Death from all cause

    Time frame: 10 years after diagnosed T2DM

  2. myocardial infarction

    MI with hospitalization

    Time frame: 10 years after diagnosed T2DM

  3. Ischemic stroke

    Ischemic stroke after diagnosed T2DM

    Time frame: 10 years after diagnosed T2DM

  4. Heart failure

    HF with hospitalization

    Time frame: 10 years after diagnosed T2DM

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071545
Lead sponsor
Samsung Medical Center
Responsible party
Ki Hong Choi (Professor, Samsung Medical Center) — Principal investigator
First posted
Jul 17, 2025
Start date
Jan 1, 2010
Primary completion
Mar 30, 2023
Completion
Sep 30, 2023
Last update
Jul 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion